Combined γ- Tocotrienol and Met Inhibitor Treatment Suppresses Mammary Cancer Cell Prolifera;on, Epithelial- to- Mesenchymal Transi;on, and Migra;on
|
|
|
- Kelley Gibson
- 5 years ago
- Views:
Transcription
1 Combined γ Tocotrienol and Met Inhibitor Treatment Suppresses Mammary Cancer Cell Prolifera;on, Epithelial to Mesenchymal Transi;on, and Migra;on Paul W. Sylvester, Ph.D. Pfizer Endowed Professor of Pharmacy College of Pharmacy University of Louisiana at Monroe, USA
2 Tocotrienols and Cancer Cancer is a group of more than 100 different diseases characterized by uncontrolled cellular growth, local tissue invasion, and distant metastases. Current strategies for treating cancer have focused on developing drugs directed against specific molecular targets associated with tumor cell growth and progression. Tocotrienols may have great potential in the prevention and treatment of cancer because of multiple mechanisms of action directed against tumor cell proliferation and viability.
3 Vitamin E and Cancer Antiproliferative Effects Tocotrienols inhibit growth factor receptor activation. Leading to the suppression of mitogenic signaling pathways. Resulting in the blockage of cell cycle progression and inhibition of cancer cell division.
4 EGFR (HER) Dimerization ATP ATP Gene Transcription Growth Proliferation Survival
5 Cells per Well (1X10 5 ) γ Tocotrienol (µm) Day 1 Day 5 Cells per Well (1X10 5 ) Erlo;nib (µm) Day 1 Day Cells per Well (1X10 5 ) 2 1 Cells per Well (1X10 5 ) Gefi;nib (µm) Day 1 Day Trastuzumab (µg/ml) Day 1 Day 5
6 Effect of Combined Treatment on SA Cell Growth MTT Assay Ki67 Staining 4 Cells per Well (1X10 5 ) C E T ET C T E G ET GT Treatment Groups G GT C Control; T γtocotrienol; E Erlotinib; G Gefitinib.
7 Effect of Combina;on Treatment on ErbB Receptor Levels ErbB3 (kda) C T E G ET GT ErbB4 C 185 ErbB3 185 ErbB4 T 185 phospho ErbB3 180 phospho ErbB4 60 αtubulin E ET
8 Effect of γ Tocotrienol on Met Tyrosine Kinase Receptor Ac;va;on
9 Met Receptor Tyrosine Kinase Met is the receptor for hepatocyte growth factor (HGF). HGF is a growth factor normally ac;ve in wound healing, liver regenera;on and organ morphogenesis. Met dysregula;on results in increase cellular prolifera;on, survival, decrease adhesion, cytoskeletal changes, and increased mo;lity. Cancers with aberrant Met ac;vity are highly aggressive, invasive and metasta;c and these pa;ents have a poor prognosis.
10 c Met Receptor Homodimeriza;on HGF ss ΩΩΩΩ ss ΩΩΩΩ P P P P P P P P
11
12
13 HGFInduced Met Activation A Cells per Well (1X10 5 ) HGF 0 ng/ml HGF 1 ng/ml HGF 5 ng/ml HGF 10 ng/ml Day0 Day1 Day2 Day3 B Time (min) HGF 100ng/ml PMet Met αtubulin
14 HGFInduced Met Activation MitogenFree HGF 10ng/ml Red: Phosphorylated Met receptors Blue: DAPI
15 Time (5 min) HGF 100ng/ml EGF 100ng/ml EGFR PEGFR Met PMet αtubulin
16 Cell Number per Well (1x10 5 ) Cell Number per Well (1x10 4 ) Cell Number per Well (1x10 4 ) SA γtocotrienol (µm) SU11274 (µm) MCF γtocotrienol (µm) SU11274 (µm) MDAMB γtocotrienol (µm) SU11274 (µm)
17 Effect of γ Tocotrienol on Met Phosphoryla;on HGF C γt 3 Red: PhosphoMet Blue: DAPI (nuclear stain)
18 Synergistic Antiproliferative Effects with Combined γtocotrienol and SU11274 Treatment MDAMB231 MDAMB231 Cell Number per Well (1x10 4 ) # # # # γtocotrienol (µm) MDAMB ND SU11274 (µm) γtocotrienol (µm) γtocotrienol (µm) SU11274 (4 µm)
19 A CLS1 MCF10A Cell Number per Well (1x10 4 ) Cell Number per Well (1x10 4 ) B γtocotrienol (µm) SU11274 (µm) γtocotrienol (µm) SU11274 (µm) CLS1 MCF10A Cell Number per Well (1x10 4 ) Cell Number per Well (1x10 4 ) γtocotrienol (µm) γtocotrienol (µm) γtocotrienol (µm) γtocotrienol (µm) SU11274 (3 µm) SU11274 (3 µm)
20 A Cells per Well (1X10 5 ) SU11274 (µm) Cells per Well (1X10 5 ) γtocotrienol (µm) B C D HGF 100ng/ml γtocotrienol (4µM) SU11274 (5.5µM) HGF 100ng/ml Time (hr) Met PMet αtubulin Met αtubulin VehicleTreated SU µm γtocotrienol 4 µm Red: Phosphorylated Met receptors Blue: DAPI
21 A Cells per Well (1X10 5 ) B HGF 100ng/ml γtocotrienol (2µM) SU11274 (3µM) Control γtocotrienol 2µM SU µM SU µM γtocotrienol 2µM Met PMet αtubulin
22 Treatment Effects on Ki67 Labeling DAPI Ki67 Merge 2µM γt 3 3µM SU 3µM SU 2µM γt 3 Control
23 γtocotrienol and SU11274 Treatment Effects on Met Signaling Control 2µM γt 3 3µM SU 2µM γt 3 3µM SU 2µM γt 3 Control 2µM γt 3 3µM SU 3µM SU MEK pmek MAPK pmapk STAT1 pstat1 STAT5 pstat5 αtubulin PI3K PDK1 ppdk1 Akt pakt PNFκB105 PTEN ppten αtubulin
24
25 A Following 24 hr Treatment 0 hr Control 2µM γt 3 3µM SU 2µM γt 3 3µM SU MDAMB231 SA B SA MDAMB231 Wound Closure (%) # # Control 2µM γt 3 3µM SU 2µM γt 3 3µM SU Control 2µM γt 3 3µM SU 2µM γt 3 3µM SU
26 Effects of Subeffective Doses of γtocotrienol and SU11274 on Epithelial and Mesenchymal Cellular Markers Control 2µM γt 3 3µM SU 2µM γt 3 3µM SU ECadherin βcatenin Cytokeratin8 Cytokeratin18 Vimentin αtubulin
27 Treatment Effects on Epithelial and Mesenchymal Cellular Markers ECadherin Control 2µM γt 3 3µM SU 2µM γt 3 3µM SU 2µM γt 3 3µM SU Mesenchymal Marker Epithelial Marker Vimentin Cytokeratin18 Cytokeratin8 βcatenin
28 Extracellular α HGF β Met Intracellular γtocotrienol SU11274 SOS Grb2 Src Shp2 GAB1 STAT1/5 Shc PI3K RAS RAF Rac/Rho FAC PDK PTEN MEK Akt IKKα/β MAPK PAC mtor NFκB Cell Proliferation Cell Adhesion, Motility Invasion, Cytoskeleton Cell Survival Transcription
29 Conclusions γtocotrienol inhibits both EGFreceptor and Metreceptor tyrosine kinase activity and mitogenic signaling. These results strongly suggest that γtocotrienol treatment may provide significant health benefit in the prevention and/or treatment of breast cancer in women with deregulated HGF/Met signaling either as monotherapy or in combination with Met Inhibitors in the treatment of highly invasive and metastatic forms of breast cancer.
30 Collaborators Sylvester El Sayed Kaddoumi Nazzal Karen P. Briski Ahmed Orabi Bilal Abuasal Hazem Ali Barry S. McIntyre Mudit Mudit Ala Abuznait Alaa Alayoubi Abdul Gapor Fathy Behery Hisham Qosa Sumit Shah Ganesh Samant Vikram Wali Sunitha Bachawal Amit Shirode Mohamed Akl Nehad Ayoub Abhita Malaviya Theja Suryatheja Parash Parajuli Roshan Tiwari Osama Alawin Acknowledgements Support American Institute for Cancer Research National Cancer Institute at NIH American Heart Association Malaysian Palm Oil Board Malaysian Palm Oil Council Carotech Hovid First Tech International Ltd.
31 Thank You
Recent Advances in Palm Tocotrienol Research: Bioavailability and Health Benefits Revisited
Recent Advances in Palm Tocotrienol Research: Bioavailability and Health Benefits Revisited Paul W. Sylvester, Ph.D. Pfizer Endowed Professor of Pharmacology, College of Pharmacy, University of Louisiana
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
Synergistic anticancer effects of combined c-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment
DOI 10.1007/s12263-011-0225-y RESEARCH PAPER Synergistic anticancer effects of combined c-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment Paul W. Sylvester Received: 23 March 2011
Signaling. Dr. Sujata Persad Katz Group Centre for Pharmacy & Health research
Signaling Dr. Sujata Persad 3-020 Katz Group Centre for Pharmacy & Health research E-mail:sujata.persad@ualberta.ca 1 Growth Factor Receptors and Other Signaling Pathways What we will cover today: How
CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION. Androgen deprivation therapy is the most used treatment of de novo or recurrent
CHAPTER VII CONCLUDING REMARKS AND FUTURE DIRECTION Stathmin in Prostate Cancer Development and Progression Androgen deprivation therapy is the most used treatment of de novo or recurrent metastatic PCa.
Supplementary Materials for
www.sciencesignaling.org/cgi/content/full/7/322/ra38/dc1 Supplementary Materials for Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer Andrea
Concise Reference. HER2 Testing in Breast Cancer. Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli
Concise Reference Testing in Breast Cancer Mary Falzon, Angelica Fasolo, Michael Gandy, Luca Gianni & Stefania Zambelli Extracted from Handbook of -Targeted Agents in Breast Cancer ublished by Springer
Fang et al. NMuMG. PyVmT unstained Anti-CCR2-PE MDA-MB MCF MCF10A
A NMuMG PyVmT 16.5+.5 47.+7.2 Fang et al. unstained Anti-CCR2-PE 4T1 Control 37.6+6.3 56.1+.65 MCF1A 16.1+3. MCF-7 3.1+5.4 MDA-M-231 42.1+5.5 unstained Secondary antibody only Anti-CCR2 SUPPLEMENTAL FIGURE
Principles of Genetics and Molecular Biology
Cell signaling Dr. Diala Abu-Hassan, DDS, PhD School of Medicine Dr.abuhassand@gmail.com Principles of Genetics and Molecular Biology www.cs.montana.edu Modes of cell signaling Direct interaction of a
Cell Signaling Regulatory Mechanisms Controlling Epithelial-Mesenchymal Transition in Carcinoma
University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 1-1-2015 Cell Signaling Regulatory Mechanisms Controlling Epithelial-Mesenchymal Transition in Carcinoma Janine Marie
Receptor mediated Signal Transduction
Receptor mediated Signal Transduction G-protein-linked receptors adenylyl cyclase camp PKA Organization of receptor protein-tyrosine kinases From G.M. Cooper, The Cell. A molecular approach, 2004, third
SUPPLEMENTARY FIGURES
SUPPLEMENTARY FIGURES Supplementary Figure S1: Fibroblast-induced elongation of cancer cells requires direct contact with living fibroblasts. A. Representative images of HT29-GFP cultured in the presence
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:.38/nature83 Supplementary figure An Overview of Experimental Flow Hypothesis: The tumor microenvironment has a significant impact on cancer cell chemoresistance. Screen Coculture
INDIVIDUALIZED THERAPY OF METASTATIC BREAST CANCER Lance A. Liotta MD PhD
INDIVIDUALIZED THERAPY OF METASTATIC BREAST CANCER Lance A. Liotta MD PhD A vision for Combining proteomic mapping with genomic analysis of the metastatic lesion 57 year old women TNBC locally recurrent
Genetics of Cancer Lecture 32 Cancer II. Prof. Bevin Engelward, MIT Biological Engineering Department
Genetics of Cancer Lecture 32 Cancer II rof. Bevin Engelward, MIT Biological Engineering Department Why Cancer Matters New Cancer Cases in 1997 Cancer Deaths in 1997 Genetics of Cancer: Today: What types
Kevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR
Kevin R. Fox, MD Rena Rowan Breast Center Abramson Cancer Center University of Pennsylvania Perelman School of MedicineR Treatment of early stage, HER2 positive breast cancer Treatment of early stage,
Reviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): The authors have presented data demonstrating activation of AKT as a common resistance mechanism in EGFR mutation positive, EGFR TKI resistant
Biol403 MAP kinase signalling
Biol403 MAP kinase signalling The mitogen activated protein kinase (MAPK) pathway is a signalling cascade activated by a diverse range of effectors. The cascade regulates many cellular activities including
Diabetes Mellitus and Breast Cancer
Masur K, Thévenod F, Zänker KS (eds): Diabetes and Cancer. Epidemiological Evidence and Molecular Links. Front Diabetes. Basel, Karger, 2008, vol 19, pp 97 113 Diabetes Mellitus and Breast Cancer Ido Wolf
Advanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
THE HALLMARKS OF CANCER
THE HALLMARKS OF CANCER ONCOGENES - Most of the oncogenes were first identified in retroviruses: EGFR (ErbB), Src, Ras, Myc, PI3K and others (slightly more than 30) - Mutated cellular genes incorporated
Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer
Sylvester Clinical and Translational Medicine 2014, 3:30 REVIEW Open Access Targeting met mediated epithelial-mesenchymal transition in the treatment of breast cancer Paul W Sylvester Abstract Mesenchymal
Molecular Cell Biology - Problem Drill 19: Cell Signaling Pathways and Gene Expression
Molecular Cell Biology - Problem Drill 19: Cell Signaling Pathways and Gene Expression Question No. 1 of 10 1. Which statement about cell signaling is correct? Question #1 (A) Cell signaling involves receiving
G-Protein Signaling. Introduction to intracellular signaling. Dr. SARRAY Sameh, Ph.D
G-Protein Signaling Introduction to intracellular signaling Dr. SARRAY Sameh, Ph.D Cell signaling Cells communicate via extracellular signaling molecules (Hormones, growth factors and neurotransmitters
EGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
Supplementary Figure 1: Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points
A. B. 8 4 Supplementary Figure : Func8onal Network Analysis of Kinases Significantly Modulated by MERS CoV Infec8on and Conserved Across All Time Points Examined. A) Venn diagram analysis of kinases significantly
Signal Transduction Pathway Smorgasbord
Molecular Cell Biology Lecture. Oct 28, 2014 Signal Transduction Pathway Smorgasbord Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Outline 1.
EGF receptor transactivation is crucial for cholinergic MAP kinase signaling in human keratinocytes
1st Electronic Conference on Molecular Science EGF receptor transactivation is crucial for cholinergic MAP kinase signaling in human keratinocytes Wymke Ockenga, Sina Kühne, Antje Banning and Ritva Tikkanen
blood mononuclear cells were stained with AAD, annexin, CD3, CD4, CD25, LAP and specific
Supplementary figure legends Figure 1: Selective expression of regulatory markers on CD4 + LAP + T cells. Human peripheral blood mononuclear cells were stained with AAD, annexin, CD3, CD4, CD25, LAP and
BASIS FOR TARGETING MET ACTIVATION MEDIATED RESISTANCE TO PI3K INHIBITION IN BREAST CANCER
Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 12-2013 BASIS FOR TARGETING MET ACTIVATION MEDIATED RESISTANCE TO PI3K
Phospholipase C γ Prof. Graham Carpenter
Graham Carpenter, h.d. rofessor of Biochemistry Cornelia Crooke Department of Biochemistry Vanderbilt University School of Medicine, Nashville, TN 1 Receptor Tyrosine Kinases GF Extracellular M Intracellular
Supplementary Figure 1
Supplementary Figure 1 Constitutive EGFR signaling does not activate canonical EGFR signals (a) U251EGFRInd cells with or without tetracycline exposure (24h, 1µg/ml) were treated with EGF for 15 minutes
Intergenic Fusions in Advanced HR+ Breast Cancer
Intergenic Fusions in Advanced HR+ Breast Cancer Leif W. Ellisen, MD, PhD Program Director, Breast Medical Oncology Disclosures: Lief W. Ellisen, MD, PhD, has disclosed no relevant financial relationships.
Enzyme-coupled Receptors. Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors
Enzyme-coupled Receptors Cell-surface receptors 1. Ion-channel-coupled receptors 2. G-protein-coupled receptors 3. Enzyme-coupled receptors Cell-surface receptors allow a flow of ions across the plasma
Regulation of Breast Tumor Kinase (Brk/PTK6) Downstream of Met Receptor Signaling Leads to Breast Cancer Cell Migration
Regulation of Breast Tumor Kinase (Brk/PTK6) Downstream of Met Receptor Signaling Leads to Breast Cancer Cell Migration A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERISTY
Breast Cancer: the interplay of biology, drugs, radiation. Prof. L. Livi Università degli Studi di Firenze. Brescia, October 3rd 4th, 2013
Breast Cancer: the interplay of biology, drugs, radiation Prof. L. Livi Università degli Studi di Firenze Brescia, October 3rd 4th, 2013 BACKGROUND (1) The complex interactions between tumor-specific signaling
Positive and Negative Regulators of Metastasis
Positive and Negative Regulators of Metastasis J. Carl Barrett Laboratory of Biosystems and Cancer Center for Cancer Research National Cancer Institute TIME SCALE OF TUMOR PROGRESSION CHEMOPREVENTION PERIOD
CAN THE CD43 MOLECULE BE CONSIDERED AS A THERAPEUTIC TAGET? Yvonne Rosenstein Instituto de Biotecnologia, UNAM
CAN THE CD43 MOLECULE BE CONSIDERED AS A THERAPEUTIC TAGET? Yvonne Rosenstein Instituto de Biotecnologia, UNAM CD43: the molecule and its signaling capacities favors a Th1 differentiation pattern and contributes
Targeted Therapies: Radiosensitizing Effects of Kinase Inhibitors
Targeted Therapies: Radiosensitizing Effects of Kinase Inhibitors Molecular and Clinical Radiobiology Workshop McGill University Health Centre, June 17-19, 2015 Bertrand J. Jean-Claude, PhD Associate Professor,
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
Supplementary Materials
Supplementary Materials Figure S1. MTT Cell viability assay. To measure the cytotoxic potential of the oxidative treatment, the MTT [3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyl tetrazolium bromide] assay
Chapter 15: Signal transduction
Chapter 15: Signal transduction Know the terminology: Enzyme-linked receptor, G-protein linked receptor, nuclear hormone receptor, G-protein, adaptor protein, scaffolding protein, SH2 domain, MAPK, Ras,
PIK3CA Mutations in HER2-Positive Breast Cancer
2016.4.29. GBCC PIK3CA Mutations in HER2-Positive Breast Cancer Seock-Ah Im, MD, PhD. Department of Internal Medicine Seoul National University Hospital Contents Introduction TCGA data HER2 signaling pathway
Many Forms of Cell-Cell Communication Regulate Tissue Function and Phenotype Physiological Functions of Gap Junctions Homeostasis buffering/sharing of ions, nutrients, and water Metabolic support nutrient
Oncogenes and Tumor. supressors
Oncogenes and Tumor supressors From history to therapeutics Serge ROCHE Neoplastic transformation TUMOR SURESSOR ONCOGENE ONCOGENES History 1911 1960 1980 2001 Transforming retrovirus RSV v-src is an oncogene
Complexity of intra- and inter-pathway loops in colon cancer and melanoma: implications for targeted therapies
Complexity of intra- and inter-pathway loops in colon cancer and melanoma: implications for targeted therapies René Bernards The Netherlands Cancer Institute Amsterdam The Netherlands Molecular versus
Therapeutic Resistance to HER2 Targeted Therapies. Neil Spector, M.D Duke Cancer Institute Duke University Medical Center
Therapeutic Resistance to HER2 Targeted Therapies Neil Spector, M.D Duke Cancer Institute Duke University Medical Center Relevant Financial Disclosures Millennium/Takeda Pharmaceuticals (consultant, sponsored
Thomas Jefferson University Annual Progress Report: 2008 Formula Grant
Thomas Jefferson University Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2012 December 31, 2012 Formula Grant Overview The Thomas Jefferson University received $3,455,597 in formula
ESMO Translational Research Fellowship ( ) Mechanisms of acquired resistance to anti growth factor receptor agents.
ESMO Translational Research Fellowship (2008 2009) Mechanisms of acquired resistance to anti growth factor receptor agents Floriana Morgillo Final report Host Institute: Mentor: AOU Seconda Università
Supplementary Materials for
www.sciencesignaling.org/cgi/content/full/7/310/ra11/dc1 Supplementary Materials for STAT3 Induction of mir-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer
Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2
Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2 SUPPLEMENTARY FIGURES AND TABLES Supplementary Figure S1:
Diagnostic test Suggested website label Description Hospitals available
Diagnostic test Suggested website label Description Hospitals available Abbott Molecular Inc, PATHVYSION HER-2 DNA Probe Kit (FISH) PathVysion kit A diagnostic tool used to determine whether a particular
BRAF: dal melanoma alla HCL
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica BRAF: dal
Cellular Physiology (PHSI3009) Contents:
Cellular Physiology (PHSI3009) Contents: Cell membranes and communication 2 nd messenger systems G-coupled protein signalling Calcium signalling Small G-protein signalling o RAS o MAPK o PI3K RHO GTPases
Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review)
INTERNATIONAL JOURNAL OF ONCOLOGY 38: 1197-1217, 2011 Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review) Sanaa Al
Supplemental Table 1. Biochemical and Cellular Potency and Selectivity of PF
Supplemental Table 1. Biochemical and Cellular Potency and Selectivity of PF- 02341066 Assay IC 50 nm Selectivity Ratio d Biochemical Activity In Vitro c-met/hgfr enzyme (Ki, nm) a 4 NA Cellular Activity
Using EGFR signaling networks to guide therapeutic strategies
Using EGFR signaling networks to guide therapeutic strategies Erica A. Golemis Program in Developmental Therapeutics Fox Chase Cancer Center November 13, 2010 Problem: the limited efficacy of therapies
Genetics and Cancer Ch 20
Genetics and Cancer Ch 20 Cancer is genetic Hereditary cancers Predisposition genes Ex. some forms of colon cancer Sporadic cancers ~90% of cancers Descendants of cancerous cells all cancerous (clonal)
Understanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma
Understanding Signaling Pathways by Modifying Sensitivity to PLX4720 in B-RAF V600E Melanoma Muska Hassan NCI-ICBP Summer Fellow Broad Institute of MIT and Harvard: Cancer Program Mentor: Cory Johannessen,
AN ABSTRACT OF THE DISSERTATION OF. Christine A. Larsen for the degree of Doctor of Philosophy in Molecular and
AN ABSTRACT OF THE DISSERTATION OF Christine A. Larsen for the degree of Doctor of Philosophy in Molecular and Cellular Biology presented on January 4, 2010. Title: Suppression of Met Signaling by the
CXC chemokine (ligand/receptor)
List of abbreviations -MEM alpha-modified minimal essential AKT protein kinase B (also abbreviated PKB) AMC 7-amino-4-methylcoumarin AP-1 activator protein 1 ARF ADP-ribosylation factor, a small GTP-binding
Discovery and Optimization of Inhibitors of STAT3 Activation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Discovery and ptimization of Inhibitors of STAT3 Activation for the Treatment of Squamous Cell Carcinoma of the Head and Neck Feng Zhang Wipf Group Research Topic Seminar 02-09-2013 1 Feng Zhang @ Wipf
Introduction: 年 Fas signal-mediated apoptosis. PI3K/Akt
Fas-ligand (CD95-L; Fas-L) Fas (CD95) Fas (apoptosis) 年 了 不 度 Fas Fas-L 力 不 Fas/Fas-L T IL-10Fas/Fas-L 不 年 Fas signal-mediated apoptosis 度降 不 不 力 U-118, HeLa, A549, Huh-7 MCF-7, HepG2. PI3K/Akt FasPI3K/Akt
Molecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG)
In vitro scratch assay: method for analysis of cell migration in vitro labeled fluorodeoxyglucose (FDG) 1 Dr Saeb Aliwaini 13/11/2015 Migration in vivo Primary tumors are responsible for only about 10%
Selecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI)
LAPATINIB-Resistance to small Molecule ErbB2 Tyrosine Kinase Inhibitor (TKI) Prim Mr Sc Dr Suzana Vasović Institute for oncology and radiology of Serbia UMOS, X Conference, 16.05.2015 Belgrade How do we
SUPPLEMENTARY INFORMATION
DOI: 1.138/ncb3355 a S1A8 + cells/ total.1.8.6.4.2 b S1A8/?-Actin c % T-cell proliferation 3 25 2 15 1 5 T cells Supplementary Figure 1 Inter-tumoral heterogeneity of MDSC accumulation in mammary tumor
Nehad M. Ayoub, Ph.D. Curriculim vitae
Nehad M. Ayoub, Ph.D. Curriculim vitae Personal Information Education Address: Jordan University of Sciences and Technology, Faculty of Pharmacy, Department of Clinical Pharmacy, Irbid 22110, Jordan Office
SUPPLEMENTARY INFORMATION
In the format provided by the authors and unedited. 2 3 4 DOI: 10.1038/NMAT4893 EGFR and HER2 activate rigidity sensing only on rigid matrices Mayur Saxena 1,*, Shuaimin Liu 2,*, Bo Yang 3, Cynthia Hajal
Supplementary Figure 1. IHC and proliferation analysis of pten-deficient mammary tumors
Wang et al LEGENDS TO SUPPLEMENTARY INFORMATION Supplementary Figure 1. IHC and proliferation analysis of pten-deficient mammary tumors A. Induced expression of estrogen receptor α (ERα) in AME vs PDA
Biology of Renal Cell Cancer. Disclosures
Biology of Renal Cell Cancer Dr Joseph Ischia Uro-oncology Fellow 14-3-2012 No patents No honorariums Not on any boards Disclosures Essendon supporter 1 Renal Cell Cancer 2% of new cancers 30% have metastatic
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression
Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta
Supplementary Figure 1. Characterization of NMuMG-ErbB2 and NIC breast cancer cells expressing shrnas targeting LPP. NMuMG-ErbB2 cells (a) and NIC
Supplementary Figure 1. Characterization of NMuMG-ErbB2 and NIC breast cancer cells expressing shrnas targeting LPP. NMuMG-ErbB2 cells (a) and NIC cells (b) were engineered to stably express either a LucA-shRNA
Targeting the ERBB family in cancer: couples therapy
OPINION Targeting the ERBB family in cancer: couples therapy Niall Tebbutt, Mikkel W. Pedersen and Terrance G. Johns Abstract The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis
Intracellular signalling pathways activated by leptin by Gema FRUHBECK. Presentation by Amnesiacs Anonymous
Intracellular signalling pathways activated by leptin by Gema FRUHBECK Presentation by Amnesiacs Anonymous Introduction to Leptin By Ahrial Young Why is Leptin important? Pleiotropic = it controls the
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs Indian Patent Application No. 1623/DEL/2014 Inventors: Prof. Kulbhushan Tikoo and Jasmine Kaur Department of Pharmacology
Review Article Tocotrienol and cancer metastasis
Review Article Tocotrienol and cancer metastasis Leanne De Silva 1 Lay Hong Chuah 1 Puvaneswari Meganathan 2 Ju-Yen Fu 2 * 1 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Selangor, Malaysia
BL 424 Chapter 15: Cell Signaling; Signal Transduction
BL 424 Chapter 15: Cell Signaling; Signal Transduction All cells receive and respond to signals from their environments. The behavior of each individual cell in multicellular plants and animals must be
Supplementary Information
Supplementary Information EGFRL858R mutant enhances lung adenocarcinoma cell invasive aility and promotes malignant pleural effusion formation through activation of the CXCL12CXCR4 pathway MengFeng Tsai
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma?
Is there a role for EGFR Tyrosine Kinase Inhibitors in recurrent glioblastoma? Juan M Sepúlveda Sánchez Neurooncology Unit Hospital Universitario 12 de Octubre. Madrid Topics 1.-EGFR pathway as a potential
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
w ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz
w ª wy xvwz A ª vw xvw P ª w} xvw w Æ w Æ V w,x Æ w Æ w Æ y,z Æ { Æ y,z, w w w~ w wy}æ zy Æ wyw{ xæ wz w xywæ xx Æ wv Æ } w x w x w Æ w Æ wy} zy Æ wz {w Æ Æ wyw{ x w Germ-line mutations in BRCA1 are associated
A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Rita Nahta, Emory University Journal Title: ISRN Oncology Volume: Volume 2012, Number 2012 Publisher: Hindawi Publishing
DOCTOR S DEGREE THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA SUMMARY DOCTOR S DEGREE THESIS THE ROLE OF EPITHELIOMESENCHYMAL TRANSITION IN THYROID CARCINOGENESIS Doctor s Degree Candidate: Mitroi Cristina Mariana (Calangiu)
Understanding acquired resistance to Lapatinib in breast cancer cells
Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 8-2010 Understanding acquired resistance to Lapatinib in breast cancer
Nature Neuroscience: doi: /nn Supplementary Figure 1
Supplementary Figure 1 EGFR inhibition activates signaling pathways (a-b) EGFR inhibition activates signaling pathways (a) U251EGFR cells were treated with erlotinib (1µM) for the indicated times followed
Effects of Second Messengers
Effects of Second Messengers Inositol trisphosphate Diacylglycerol Opens Calcium Channels Binding to IP 3 -gated Channel Cooperative binding Activates Protein Kinase C is required Phosphorylation of many
Understanding PI3K/mTOR/MEK signalling in breast cancer. Euphemia Leung Auckland Cancer Society Research Centre University of Auckland
Understanding PI3K/mTOR/MEK signalling in breast cancer Euphemia Leung Auckland Cancer Society Research Centre University of Auckland Receptor status of human breast cancer On a popula>on basis ER+/PR+
PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
Protein tyrosine kinase signaling
rotein tyrosine kinase signaling Serge ROCHE CRBM CNRS/Montpellier University serge.roche@crbm.cnrs.fr rotein phosphorylation on Tyr A central mechanism to control cell communication in a multicellular
mtor plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions
Supplementary Information mtor plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions Shyuichiro Matsubara 1, Qiang Ding 1, Yumi Miyazaki 1, Taisaku Kuwahata
Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer Sunday, Apr 18, 2010, 2:25 PM - 2:40 PM
Abstract Print View Page 1 of 1 Presentation Abstract Abstract Number: Presentation Title: Presentation Time: Location: Author Block: 22 Cyclin E amplification, a novel mechanism of resistance to trastuzumab
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
CHAPTER 3: EGFR ACTIVATION IMPACTS ON FAK PROTEIN EXPRESSION AND PHOSPHORYLATION STATUS IN HOSCC CELL LINES
CHAPTER 3: EGFR ACTIVATION IMPACTS ON FAK PROTEIN EXPRESSION AND PHOSPHORYLATION STATUS IN HOSCC CELL LINES 3.1 Introduction Developmental processes such as cell migration depend on signals from both the
Mechanism and Therapeutic Potential of Statin-Mediated Inhibition of Tyrosine Kinase Receptors. Tong Tong Zhao
Mechanism and Therapeutic Potential of Statin-Mediated Inhibition of Tyrosine Kinase Receptors Tong Tong Zhao Thesis submitted to the Faculty of Graduate and Postdoctoral Studies In partial fulfillment